

Involvement of Cytochrome P450, Glutathione S-Transferase, and Epoxide Hydrolase in the Metabolism of Aflatoxin B₁ and Relevance to Risk of Human Liver Cancer

F. Peter Guengerich,¹ William W. Johnson,¹ Yune-Fang Ueng,¹ Hiroshi Yamazaki,² and Tsutomu Shimada²

¹Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee;

²Osaka Prefectural Institute of Public Health, Osaka, Japan

In recent years there has been considerable interest in the effect of variations in activities of xenobiotic-metabolizing enzymes on cancer incidence. This interest has accelerated with the characterization of human enzymes, both those involved in activation and detoxication, and the development of methods for analyzing genetic polymorphisms. However, progress in epidemiology has been slow and the contributions of polymorphisms to risks from individual chemicals and mixtures are often controversial. A series of studies is presented to show the complexities encountered with a single chemical, aflatoxin B₁ (AFB₁). AFB₁ is oxidized by human cytochrome P450 enzymes to several products. Only one of these, the 8,9-*exo*-epoxide, appears to be mutagenic and the others are detoxication products. P450 3A4, which can both activate and detoxicate AFB₁, is found in the liver and the small intestine. In the small intestine, the first contact after oral exposure, epoxidation would not lead to liver cancer. The (nonenzymatic) half-life of the epoxide has been determined to be approximately 1 sec at 23°C and neutral pH. Although the half-life is short, AFB₁-8,9-*exo*-epoxide does react with DNA and glutathione S-transferase. Levels of these conjugates have been measured and combined with the rate of hydrolysis in a kinetic model to predict constants for binding of the epoxide with DNA and glutathione S-transferase. A role for epoxide hydrolase in alteration of AFB₁ hepatocarcinogenesis has been proposed, although experimental evidence is lacking. Some inhibition of microsome-generated genotoxicity was observed with rat epoxide hydrolase; further information on the extent of contribution of this enzyme to AFB₁ metabolism is not yet available. — Environ Health Perspect 104(Suppl 3):557–562 (1996)

Key words: aflatoxin B₁, cytochrome P450, glutathione, glutathione S-transferase, epoxide hydrolase, metabolism of mycotoxins, metabolism of chemical carcinogens

Introduction

The role of enzymatic transformation in the activation and detoxication of chemical carcinogens has been recognized for half a century (1). Studies on these enzymes have shown their multiplicity in many cases, as well as the large extent of

variation of levels of individual enzymes that can occur (2). With experimental animal systems, there is considerable evidence that alterations in levels of some of these enzymes can have dramatic effects in influencing the incidence of cancer from

chemical carcinogens, both in the classical initiation and promotion phases (3–7). This background in experimental models has led to hypotheses that variations in the activities of individual enzymes involved in xenobiotic transformation influence cancer incidence in humans (7,8). In the late 1980s it became possible to assign roles in the activation of many chemical carcinogens to individual P450 enzymes on the basis of *in vitro* results (8,9) (Table 1). The same approaches have been used with other enzymes such as GST and *N*-acetyltransferase. In some cases, the dominance of a particular enzyme (especially cytochrome P450) in the metabolism of a drug has made it possible to make *in vivo* evaluations of the contributions to the human metabolism of a carcinogen, especially if low levels of the carcinogen can be administered to humans (7,8,11).

The above information has led to studies involving what is often referred to as molecular epidemiology, particularly in the effort to associate cancer risks with levels of enzymes or with genetic polymorphisms in the enzymes. The difficulty in the approach may be exemplified by the results of efforts to relate levels of P450 2D6 with tobacco-induced lung cancer, where equivocal results have been obtained in different laboratories over the course of a decade (12–15). Part of the difficulty in this situation may be a result of the myriad of potential carcinogens found in tobacco smoke and the lack of P450 2D6 to dominate in the activation of any of these (16–18).

Aflatoxin B₁ (AFB₁) is generally considered to play a major role in human liver cancer in some parts of the world (19,20), and much is now known about its mechanism of genotoxicity, which appears to be the result of the formation of a single initial DNA adduct (at the guanyl N7 atom) (21,22). We have considered some of the complexities of the metabolism of AFB₁ and the relevance to efforts to implicate individual enzyme levels as factors in risk.

Methods

Chemicals

AFB₁ was purchased from Sigma Chemical Co. (St. Louis, MO) and was further purified by thin-layer chromatography under dim light (silica gel G) before use in

This paper was presented at the 2nd International Conference on Environmental Mutagens in Human Populations held 20–25 August 1995 in Prague, Czech Republic. Manuscript received 22 November 1995; manuscript accepted 28 November 1995.

This work was supported in part by United States Public Health Service Grants CA44353 and ES00267 and by grants from the Ministry of Science, Culture, and Education of Japan.

Address correspondence to: Dr. F. Peter Guengerich, Department of Biochemistry and Center in Molecular Toxicology, 638 Medical Research Building I, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Telephone: (615) 322-2261. Fax: (615) 322-3141. E-mail: guengerich@toxicology.mc.vanderbilt.edu

Abbreviations used: AFB₁, aflatoxin B₁; AFQ₁, aflatoxin Q₁; AFM₁, aflatoxin M₁; GSH, glutathione; GST, glutathione S-transferase; EH, epoxide hydrolase; GS-AFB₁, 8-(S-glutathionyl),9-hydroxy AFB₁.

Table 1. Major carcinogenic substrates for human P450 enzymes.

P450	Substrate
1A1	Polycyclic hydrocarbons
1A2	Aryl amines Heterocyclic amines
2A6	Nitrosamines
2E1	Nitrosamines Benzene Vinyl monomers Halogenated hydrocarbons
3A4	Aflatoxins Polycyclic hydrocarbon dihydrodiols Pyrrolizidine alkaloids Some aryl amines Mercapturic acids

Data from Guengerich and Shimada (8,10).

the genotoxicity experiments. AFB₁-8,9-epoxide was synthesized with the use of dimethyldioxirane (23) by T. M. Harris, and the *exo* isomer was crystallized from a (CH₃)₂CO:CHCl₃ mixture (24). 8-(*S*-glutathionyl), 9-hydroxy AFB₁ (GS-AFB₁) (25) was also a gift from Harris' laboratory. AFB₁-8,9-dihydrodiol was prepared by the addition of aqueous HCl to AFB₁-8,9-epoxide.

Enzymes

Recombinant human P450s 1A2 (26) and 3A4 (27) were produced in *Escherichia coli* and purified as described. Rabbit liver NADPH-P450 reductase (28) and cytochrome *b*₅ (29) were isolated as described. Recombinant (rat) glutathione *S*-transferase (GST) 3-3 was a gift from R. N. Armstrong. Rat and human liver epoxide hydrolases (EHs) were purified using modifications of procedures published elsewhere (30).

Assays

GS-AFB₁ (products of *exo* and *endo* epoxides) and AFB₁-8,9-dihydrodiol were separated by high-performance liquid chromatography (HPLC) and quantified (A₃₆₀) as described elsewhere (25,31). Genotoxicity assays involved measurement of the *umu* (SOS) response in *Salmonella typhimurium* TA1535 harboring the plasmid pSK1001 using general procedures described elsewhere (32). Experiments involving kinetics of AFB₁-8,9-*exo*-epoxide hydrolysis were done using an Applied Photophysics SX-17-MV system (Leatherbarrow, U.K.) equipped with fluorescence and UV-diode array detectors and software for analysis of results. Kinetic simulations were done with the KINSIM (33) software run on a

Macintosh PowerMac computer (Apple Computer, Inc., Cupertino, CA) equipped with a Software FPU coprocessing simulator.

Results

Oxidation of AFB₁ by P450 Enzymes

P450 3A4 has been shown to play a major role in the activation of AFB₁ due to its intrinsic activity towards this substrate and the high level of this enzyme present in human liver (9,31,34-37) (Table 2). P450 1A2 and some other human P450s can also contribute, but they play a lesser role, even at relatively low AFB₁ concentrations (31,35,36,38,39). P450 3A4 forms only the genotoxic AFB₁-8,9-*exo*-epoxide; P450 1A2 forms both the *exo* and the nongenotoxic *endo* isomers (Figure 1)(31).

P450s can also detoxicate AFB₁ (Figure 1). P450 3A4 forms AFQ₁, the 3 α -hydroxylation product, which does not appear to be a good substrate for epoxidation (37). P450 1A2 forms AFM₁ (by 9a hydroxylation), which also seems to be a detoxication product (31,37). In animal studies, the induction of P450 1A2 and production of AFM₁ have been reported to account for the lower levels of AFB₁-induced hepatocellular cancer after administration of polycyclic hydrocarbons (40,41). Which of the human P450s form aflatoxin P₁ is not known.

Table 2. Rates of oxidation of AFB₁ by recombinant human P450s.

P450	Product formed, nmol/min/nmol P450			
	AFQ ₁	AFM ₁	AFB ₁ -8,9-epoxide	
			<i>exo</i>	<i>endo</i>
1A1	<0.05	0.14	<0.05	<0.05
1A2	0.2	1.5	0.15	0.15
3A4	6.8	<0.05	1.35	<0.05

Data from Ueng et al. (31).

Flavonoids can modulate the metabolism of AFB₁, as first reported by Conney's laboratory (42,43). α -Naphthoflavone inhibits all activities of P450 1A2 (31); it also inhibits AFB₁ 3 α -hydroxylation (to form AFQ₁) by P450 3A4 but stimulates 8,9-epoxidation (31,37). The influence on the kinetic profiles is postulated to reflect an allosteric mechanism (44).

Conjugation of AFB₁-8,9-epoxides with Glutathione

Several lines of evidence suggest that the extent of glutathione (GSH) conjugation of AFB₁-8,9-epoxide is a major factor in influencing the risk of different experimental animal species to AFB₁-induced hepatocellular carcinoma (Figure 2)(6,45). At neutral pH, there is essentially no nonenzymatic reaction of GSH with AFB₁-8,9-epoxide (25). With crude liver cytosolic




Figure 1. Oxidation of AFB₁ by P450s.

fractions, the order of (enzymatic) GST activity is mouse > rat > human (25). The relative extent of GSH-AFB₁ conjugate formation by some human GSTs is shown in Table 3.

AFB₁-8,9-epoxide Hydrolysis

Previous work has shown that the *exo* epoxide, the major isomer formed (24,31), is also less stable in CH₃OH/H₂O mixtures (46). Other work has suggested that the half-life (t_{1/2}) of the *exo* epoxide was < 10 sec (47).


Preliminary studies have indicated that the UV spectrum of AFB₁-8,9-dihydrodiol is distinct from that of the epoxide (Figure 3A). The fluorescence spectra are even more distinct, with the dihydrodiol having more than two orders of magnitude more fluorescence than the epoxide. Kinetics of hydrolysis were measured in a stopped-flow apparatus in a pH 7.0 buffer, with 9% (CH₃)₂CO present (final concentration). The t_{1/2} was approximately 1 sec when either UV or fluorescence traces were measured (Figure 3B).

Further studies indicated that the observed hydrolysis rate constant was rather constant between pH 4 and pH 9 but was increased at < pH 4, with a slope of the log₁₀ observed versus pH having a slope of unity.


Interaction of AFB₁-8,9-*exo*-epoxide with Glutathione S-Transferase 3-3 and DNA

In earlier studies the relative rates of reaction of GSTs with AFB₁-8,9-epoxides had been estimated by quantitation of GSH-AFB₁ with fixed concentrations of GSTs and time points (Table 3) (25). To examine the aspects of these interactions, we measured the extent of GS-AFB₁ formation after mixing varying concentrations of AFB₁-8,9-*exo*-epoxide and GST 3-3 in the presence of GSH (Figure 4).

To estimate constants for the reactions, we set up the equations



and



where $A = [\text{AFB}_1\text{-8,9-}i>exo\text{-epoxide}]$

$B = [\text{GST 3-3}]$

$C = [\text{GS-AFB}_1]$

and $D = [\text{AFB}_1\text{-8,9-dihydrodiol}]$

and utilized the KINSIM program (33) to evaluate various values of K_{eq} and k_1 that would give match values of C and

D experimentally measured at various concentrations of A and B (Figure 4). The same approach was used with DNA and previously measured values (48) and with $B = \text{DNA}$ and $C = \text{DNA } N^7\text{-guanyl adduct}$. The estimates are presented in Table 4, along with the measured k_o .

Table 3. Conjugation of AFB₁-8,9-epoxides by purified human GSTs.

GST	GSH-AFB ₁ conjugate formed, nmol/mg GST protein ^a	
	<i>exo</i> -8,9-Epoxide	<i>endo</i> -8,9-Epoxide
A1-1	0.04	<0.01
A2-2	0.02	<0.01
M1-1	0.55	1.35
M3-3	<0.14	<0.14
P1-1	<0.06	<0.06

Data from Raney et al. (25). ^aAFB₁ (10:1 *exo:endo* mixture) was added to a 50 μl solution of each enzyme to give a final concentration of 55 μM AFB₁-8,9-epoxide. CH₃CO₂H was added to precipitate protein, and the GSH-AFB₁ conjugates were analyzed by HPLC. The results presented are means of duplicate experiments (25).




Figure 2. Reactions of AFB₁ 8,9-oxides.





Figure 3. Nonenzymatic hydrolysis of AFB₁-8,9-*exo*-epoxide. *A*, A solution of AFB₁-8,9-*exo*-epoxide [in dry (CH₃)₂CO] was mixed with 10 volumes of 50 mM potassium phosphate buffer (pH 7.0) at 23°C in the stopped-flow spectrophotometer and UV spectra were recorded approximately every 20 msec with the use of a diode array detector. *B*, In a similar experiment, the increase in fluorescence (excitation 357 nm, emission 452 nm) was recorded as a function of time.




Figure 4. Formation of GS-AFB₁ by GST 3-3. AFB₁-8,9-*exo*-epoxide, in dry acetone, was mixed with varying amounts of GST 3-3 and 10 mM GSH in 50 µl of 50 mM potassium phosphate buffer (pH 7.4) at 23°C. The final concentration of AFB₁-8,9-*exo*-epoxide was 4 (●), 12 (◆), or 24 (■) mM. After 15 sec, 20 ml of 2.0 M aqueous CH₃CO₂H was added and the protein was precipitated by centrifugation at 3 × 10³ × g for 10 min. Aliquots of the supernatant were analyzed for AFB₁-8,9-dihydrodiol and GS-AFB₁ by HPLC as described elsewhere (25,31).

Table 4. Reactions of AFB₁ 8,9-*exo* oxide with GST 3-3 or DNA.

$$k_o = k_H + a_H + k_o'$$

$$k_o' = 0.58/\text{sec}$$

$$k_H = 2.0 \times 10^3/\text{M}/\text{sec}$$

B	K _{eq}	k ₁
GST 3-3	0.03 µM	0.08/sec
DNA	0.05 µM	0.20/sec

(See text for kinetic model.)




Figure 5. Effect of purified EH on genotoxicity of AFB₁ activated by P450 3A4. AFB₁ (20 µM) was activated in the presence of a recombinant P450 3A4 (10 nM)-based oxidation system (31) in the presence of an NADPH-generating system, *S. typhimurium* TA1535 containing plasmid pSK1001, and the indicated concentrations of purified rat (●) or human (▲, ■) EH (the latter two samples were prepared from human liver samples, HL96 and HL105, of two different individuals). The response to heat-inactivated rat EH is also shown (○). The *umu* response was monitored by β-galactosidase response and is expressed as described by Shimada et al. (32).

Interactions of AFB₁-8,9-*exo*-epoxide and Epoxide Hydrolase

The action of EH on AFB₁-8,9-*exo*-epoxide has been postulated before (49,50), but definite results regarding this possibility are not available. The rapid rate of non-enzymatic hydrolysis (Figure 3B, Table 4) renders direct measurement of the reaction difficult. We could not see a definite effect of purified rat human EH on the recovery of N⁷-guanyl DNA adducts in experiments where AFB₁-8,9-epoxide was mixed with DNA or where EHs were added to a system containing P450 3A4 (plus all accessory components needed for oxidation) and a suboptimal amount of GST. However, in other experiments we have been able to increase the observed rate of AFB₁-8,9-*exo*-epoxide hydrolysis (from 0.64 to 0.78/sec) in the presence of 19 µM rat EH. This result needs to be further evaluated.

We also used another system in which a very low concentration of P450 3A4 (and accessory components) was used to activate AFB₁ in an *S. typhimurium* system in which an *umu* end point was measured (Figure 5). Under such conditions a very high ratio of EH:P450 can be achieved. Both rat and human EH could partially inhibit the genotoxicity response under these conditions.

Summary

Further studies are needed to evaluate the role of EH in the metabolism of AFB₁-8,9-epoxide. The report of McGlynn et al. (49) is surprising in that the EH allelic variant was linked with higher levels of AFB₁-albumin adduct, even though the major AFB₁ protein adduct is thought to be derived from AFB₁-8,9-dihydrodiol (51). The dihydrodiol results from the enzymatic or nonenzymatic hydrolysis of the epoxide. The possibility of direct reaction of protein with the epoxide cannot be ruled out at this time; however, the effect of the allelic variation on the catalytic activity of EH is not well established. The report of lower activity is the result of lower levels of expression in a transient system, not intrinsic catalytic activity (52).

The complexity of the enzyme systems involved in the metabolism of AFB₁ points out the difficulties in doing molecular epidemiology studies, even when a single chemical carcinogen has been identified. The roles of at least two P450s in the activation process have been considered. There is suggestive evidence that human GSTs in the alpha, mu, and theta families may all have roles in the detoxication of the epoxide (25,53-55). Further work is needed to establish whether there is a role for EH. With all of the enzymes, there is a need




Figure 6. Complications involved in the metabolism of AFB₁ and relevance to hepatocellular cancer.

to consider the stereochemistry of the epoxide, which has been shown to be critical in genotoxicity.

We anticipate that more careful analysis of the kinetics of the reactions under consideration here will provide insight into competition of detoxication enzymes with DNA (Figure 2). However, even with this information there are considerable problems in the knowledge base underlying efforts in molecular epidemiology (Figure 6). The P450s both activate and detoxicate

AFB₁, and the effect of inducing individual P450s is not easy to predict. Moreover, P450 3A4 is expressed in small intestine, the site of absorption of orally ingested AFB₁. The extent of detoxication there is unknown. Further, even activation of AFB₁ and DNA alkylation in the small intestine may be considered to be a detoxication process since the cells are sloughed rapidly and cancers of the small intestine are very rare. Other aspects regarding enzymes of activation and detoxication

mentioned in Figure 6 have been discussed above. Other aspects not discussed here, but which may be involved, include whether the N⁷-guanyl adduct or its ring-opened form is more mutagenic, the role of DNA repair, aflatoxin intake, the intraindividual variability of levels of the enzymes under consideration during the course of tumor initiation and development, and hepatitis B virus status.

REFERENCES

- Mueller GC, Miller JA. The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. *J Biol Chem* 176:535-544 (1948).
- Guengerich FP. Metabolic activation of carcinogens. *Pharmacol Ther* 54:17-61 (1992).
- Conney AH, Miller EC, Miller JA. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. *Cancer Res* 16:450-459 (1956).
- Nebert DW. The *Ah* locus: genetic differences in toxicity, cancer, mutation, and birth defects. *Crit Rev Toxicol* 20:153-174 (1989).
- Boberg EW, Liem A, Miller EC, Miller JA. Inhibition by pentachlorophenol of the initiating and promoting activities of 1'-hydroxysafrole for the formation of enzyme-altered foci and tumors in rat liver. *Carcinogenesis* 8:531-539 (1987).
- Bolton MG, Muñoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, Kensler TW. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. *Cancer Res* 53:3499-3504 (1993).
- Guengerich FP. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. *Cancer Res* 48:2946-2954 (1988).
- Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. *Chem Res Toxicol* 4:391-407 (1991).
- Shimada T, Iwasaki M, Martin MV, Guengerich FP. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by *umu* gene response in *Salmonella typhimurium* TA1535/pSK1002. *Cancer Res* 49:3218-3228 (1989).
- Guengerich FP, Shimada T. Human cytochrome P-450 enzymes and chemical carcinogenesis. In: *Human Drug Metabolism: From Molecular Biology to Man* (Jeffrey EH, ed). Boca Raton, FL: CRC Press, 1993;5-12.
- Guengerich FP. Human cytochrome P450 enzymes. In: *Cytochrome P450* (Ortiz de Montellano PR, ed). New York: Plenum Press, 1995;473-535.
- Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. *Nature* 312:169-170 (1984).
- Drakoulis N, Minks T, Ploch M, Otte F, Heinemeyer G, Kampf D, Lodenkemper R, Roots I. Questionable association of debrisoquine hydroxylator phenotype and risk for bronchial carcinoma. *Acta Pharmacol Toxicol* 59(Suppl 5):220 (1986).
- Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. *Environ Health Perspect* 102(Suppl 9):55-61 (1994).
- Boobis AR, Davies DS. Debrisoquine oxidation phenotype and susceptibility to lung cancer. *Br J Clin Pharmacol* 30:653-656 (1990).
- Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough RA, Martin MV, Guengerich FP. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. *Cancer Res* 45:2116-2122 (1985).
- Shimada T, Guengerich FP. Activation of amino- α -carboline, 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine and a copper phthalocyanine cellulose extract of cigarette smoke condensate by cytochrome P-450 enzymes in rat and human liver microsomes. *Cancer Res* 51:5284-5291 (1991).
- Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. *Carcinogenesis* 12:1197-1201 (1991).
- Busby WF, Wogan GN. Aflatoxins. In: *Chemical Carcinogens* (Searle CE, ed). Washington: American Chemical Society, 1984;945-1136.
- Wogan GN. Aflatoxins as risk factors for hepatocellular carcinoma in humans. *Cancer Res* 52(Suppl 7):2114s-2118s (1992).
- Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Büchi G, Wogan GN. Structural identification of the major DNA adduct formed by aflatoxin B₁ *in vitro*. *Proc Natl Acad Sci USA* 74:1870-1874 (1977).
- Lin JK, Miller JA, Miller EC. 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy-aflatoxin B₁, a major acid hydrolysis product of aflatoxin B₁-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver *in vivo*. *Cancer Res* 37:4430-4438 (1977).
- Baertschi SW, Raney KD, Stone MP, Harris TM. Preparation of the 8,9-epoxide of the mycotoxin aflatoxin B₁: the ultimate carcinogenic species. *J Am Chem Soc* 110:7929-7931 (1988).
- Raney KD, Coles B, Guengerich FP, Harris TM. The *endo* 8,9-epoxide of aflatoxin B₁: a new metabolite. *Chem Res Toxicol* 5:333-335 (1992).
- Raney KD, Meyer DJ, Ketterer B, Harris TM, Guengerich FP. Glutathione conjugation of aflatoxin B₁ *exo* and *endo* epoxides by rat and human glutathione S-transferases. *Chem Res Toxicol* 5:470-478 (1992).
- Sandhu P, Guo Z, Baba T, Martin MV, Tukey RH, Guengerich FP. Expression of modified human cytochrome P450 1A2 in *Escherichia coli*: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. *Arch Biochem Biophys* 309:168-177 (1994).
- Gillam EMJ, Baba T, Kim B-R, Ohmori S, Guengerich FP. Expression of modified human cytochrome P450 3A4 in *Escherichia coli* and purification and reconstitution of the enzyme. *Arch Biochem Biophys* 305:123-131 (1993).
- Yasukochi Y, Masters BSS. Some properties of a detergent-solubilized NADPH-cytochrome *c* (cytochrome P-450) reductase

- purified by biospecific affinity chromatography. *J Biol Chem* 251:5337-5344 (1976).
29. Funae Y, Imaoka S. Simultaneous purification of multiple forms of rat liver microsomal cytochrome P-450 by high-performance liquid chromatography. *Biochim Biophys Acta* 842:119-132 (1985).
 30. Guengerich FP, Wang P, Mitchell MB, Mason PS. Rat and human liver microsomal epoxide hydratase. Purification and evidence for the existence of multiple forms. *J Biol Chem* 254:12248-12254 (1979).
 31. Ueng Y-F, Shimada T, Yamazaki H, Guengerich FP. Oxidation of aflatoxin B₁ by bacterial recombinant human cytochrome P450 enzymes. *Chem Res Toxicol* 8:218-225 (1995).
 32. Shimada T, Oda Y, Yamazaki H, Mimura M, Guengerich FP. SOS function tests for studies of chemical carcinogenesis in *Salmonella typhimurium* TA 1535/pSK1002, NM2009, and NM3009. In: *Methods in Molecular Genetics*. Vol 5 (Adolph KW, ed). Orlando, FL: Academic Press, 1994;342-355.
 33. Barshop BA, Wrenn RF, Frieden C. Analysis of numerical methods for computer simulation of kinetic processes: development of KINSIM—a flexible, portable system. *Anal Biochem* 130:134-145 (1983).
 34. Shimada T, Guengerich FP. Evidence for cytochrome P-450_{NF}, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. *Proc Natl Acad Sci USA* 86:462-465 (1989).
 35. Aoyama T, Yamano S, Guzelian PS, Gelboin HV, Gonzalez FJ. 5 of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B₁. *Proc Natl Acad Sci USA* 87:4790-4793 (1990).
 36. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B₁ metabolism in human liver. *Proc Natl Acad Sci USA* 87:8306-8310 (1990).
 37. Raney KD, Shimada T, Kim D-H, Groopman JD, Harris TM, Guengerich FP. Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q₁ as a detoxication product of aflatoxin B₁. *Chem Res Toxicol* 5:202-210 (1992).
 38. Crespi CL, Penman BW, Leakey JAE, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL, Langenbach R. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. *Carcinogenesis* 11:1293-1300 (1990).
 39. Yun C-H, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. *Mol Pharmacol* 40:679-685 (1991).
 40. Faleto MB, Koser PL, Battula N, Townsend GK, Maccubbin AE, Gelboin HV, Gurtoo HL. Cytochrome P₃-450 cDNA encodes aflatoxin B₁-4-hydroxylase. *J Biol Chem* 263:12187-12189 (1988).
 41. Koser PL, Faleto MB, Maccubbin AE, Gurtoo HL. The genetics of aflatoxin B₁ metabolism: association of the induction of aflatoxin B₁-4-hydroxylase with the transcriptional activation of cytochrome P₃-450 gene. *J Biol Chem* 263:12584-12595 (1988).
 42. Buening MK, Fortner JG, Kappas A, Conney AH. 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B₁ to mutagens by human liver. *Biochem Biophys Res Commun* 82:348-355 (1978).
 43. Buening MK, Chang RL, Huang MR, Fortner JG, Wood AW, Conney AH. Activation and inhibition of benzo(a)pyrene and aflatoxin B₁ metabolism in human liver microsomes by naturally occurring flavonoids. *Cancer Res* 41:67-72 (1981).
 44. Guengerich FP, Kim B-R, Gillam EMJ, Shimada T. Mechanisms of enhancement and inhibition of cytochrome P450 catalytic activity. In: *Proceedings of the 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology* (Lechner MC, ed). Chichester, U.K.: John Libbey Eurotext, 1994;97-101.
 45. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B₁-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. *Cancer Res* 51:5501-5506 (1991).
 46. Iyer R, Coles B, Raney KD, Thier R, Guengerich FP, Harris TM. DNA adduction by the potent carcinogen aflatoxin B₁ mechanistic studies. *J Am Chem Soc* 116:1603-1609 (1994).
 47. Baertschi SW, Raney KD, Shimada T, Harris TM, Guengerich FP. Comparison of rates of enzymatic oxidation of aflatoxin B₁, aflatoxin G₁, and sterigmatocystin and activities of the epoxides in forming guanyl-N⁷ adducts and inducing different genetic responses. *Chem Res Toxicol* 2:114-122 (1989).
 48. Raney KD, Gopalakrishnan S, Byrd S, Stone MP, Harris TM. Alteration of the aflatoxin cyclopentenone ring to a δ-lactone reduces intercalation with DNA and decreases formation of guanine N⁷ adducts by aflatoxin epoxides. *Chem Res Toxicol* 3:254-261 (1990).
 49. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia X-L, Baffoe-Bonnie A, Ofori-Adjei D, Chen G-C, London WT, Shen F-M, Buetow KH. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B₁. *Proc Natl Acad Sci USA* 92:2384-2387 (1995).
 50. Ch'ih JJ, Lin T, Devlin TM. Activation and deactivation of aflatoxin B₁ in isolated rat hepatocytes. *Biochem Biophys Res Commun* 110:668-674 (1983).
 51. Sabbioni G, Skipper PL, Büchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B₁ *in vivo* in rats. *Carcinogenesis* 8:819-824 (1987).
 52. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression *in vitro* of amino acid variants. *Hum Mol Genet* 3:421-428 (1994).
 53. Liu YH, Taylor J, Linko P, Lucier GW, Thompson CL. Glutathione S-transferase μ in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts. *Carcinogenesis* 12:2269-2275 (1991).
 54. Languoët S, Coles B, Morel F, Becquemont L, Beaune PH, Guengerich FP, Ketterer B, Guillouzo A. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B₁ metabolism in human hepatocytes in primary culture. *Cancer Res* 55:5574-5579 (1995).
 55. Shimada T, Yamazaki H, Oda Y, Hiratsuka A, Watabe T, Guengerich FP. Activation and inactivation of carcinogenic dihaloalkanes and other compounds by glutathione S-transferase 5-5 in *Salmonella typhimurium* tester strain NM5004. *Chem Res Toxicol* 9:333-340 (1996).